The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non–small-cell Lung Cancer Through Altering STAT3 Expression

Molecular Therapy Nucleic Acids

Volumn 5, Issue , 2016, Pages e387-

  Sun, Cheng Cao ^a   Li, Shu Jun ^a,b   Zhang, Feng ^a   Zhang, Ya Dong ^c   Zuo, Zhen Yu ^d   Xi, Yong Yong ^a   Wang, Liang ^a   Li, De Jia ^a  

^a WUHAN UNIVERSITY   (China)

^b Center for Disease Control and Prevention of Wuhan   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

drug resistance; miR 9600; non small cell lung cancer; STAT3; tumorigenesis

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 9600; PACLITAXEL; STAT3 PROTEIN; UNCLASSIFIED DRUG; CASPASE 3; CASPASE 7; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; DICER; GELATINASE A; GELATINASE B; MATRILYSIN; MESSENGER RNA; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RETINOBLASTOMA PROTEIN;

3' UNTRANSLATED REGION; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER TISSUE; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE FUNCTION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; MALE; METASTASIS INHIBITION; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN RNA BINDING; TUMOR INVASION; A-549 CELL LINE; ANIMAL CELL; CANCER GENE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CELL PROLIFERATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; DRUG POTENTIATION; ENZYME ACTIVITY; GENE EXPRESSION; IC50; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG PARENCHYMA; MIGRATION INHIBITION; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL LUNG CARCINOMA; UPREGULATION;

EID: 85015216712     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2016.96     Document Type: Article

References (54)

1. 1 Chen, K, He, H, Xie, Y, Zhao, L, Zhao, S, Wan, X, et al. miR-125a-3p and miR-483-5p promote adipogenesis via suppressing the RhoA/ROCK1/ERK1/2 pathway in multiple symmetric lipomatosis. Sci Rep, 5, 2015, 11909.
2. 2 Yan, S, Xu, Z, Lou, F, Zhang, L, Ke, F, Bai, J, et al. NF-κB-induced microRNA-31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis. Nat Commun, 6, 2015, 7652.
3. 3 Li, Z, Song, Y, Liu, L, Hou, N, An, X, Zhan, D, et al. miR-199a impairs autophagy and induces cardiac hypertrophy through mTOR activation. Cell Death Differ, 2015.
4. 4 Tang, X, Hou, Y, Yang, G, Wang, X, Tang, S, Du, YE, et al. Stromal miR-200s contribute to breast cancer cell invasion through CAF activation and ECM remodeling. Cell Death Differ 23 (2015), 132–145.
5. 5 Sun, C, Sang, M, Li, S, Sun, X, Yang, C, Xi, Y, et al. Hsa-miR-139-5p inhibits proliferation and causes apoptosis associated with down-regulation of c-Met. Oncotarget 6 (2015), 39756–39792.
6. 6 Schiller, JH, Harrington, D, Belani, CP, Langer, C, Sandler, A, Krook, J, et al., Eastern Cooperative Oncology Group, Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002), 92–98.
7. 7 Laskin, JJ, Sandler, AB, State of the art in therapy for non-small cell lung cancer. Cancer Invest 23 (2005), 427–442.
8. 8 Grosswendt, S, Filipchyk, A, Manzano, M, Klironomos, F, Schilling, M, Herzog, M, et al. Unambiguous identification of miRNA:target site interactions by different types of ligation reactions. Mol Cell 54 (2014), 1042–1054.
9. 9 Belgardt, BF, Ahmed, K, Spranger, M, Latreille, M, Denzler, R, Kondratiuk, N, et al. The microRNA-200 family regulates pancreatic beta cell survival in type 2 diabetes. Nat Med 21 (2015), 619–627.
10. 10 Yoo, JK, Jung, HY, Lee, JM, Yi, H, Oh, SH, Ko, HY, et al. The novel miR-9500 regulates the proliferation and migration of human lung cancer cells by targeting Akt1. Cell Death Differ 21 (2014), 1150–1159.
11. 11 Li, Y, Kuscu, C, Banach, A, Zhang, Q, Pulkoski-Gross, A, Kim, D, et al. miR-181a-5p inhibits cancer cell migration and angiogenesis via downregulation of matrix metalloproteinase-14. Cancer Res 75 (2015), 2674–2685.
12. 12 Jin, M, Zhang, T, Liu, C, Badeaux, MA, Liu, B, Liu, R, et al. miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells. Cancer Res 74 (2014), 4183–4195.
13. 13 Sun, C., Li, S, Yang, C, Xi, Y, Wang, L, Zhang, F, et al. MicroRNA-187-3p mitigates non-small cell lung cancer (NSCLC) development through down-regulation of BCL6. Biochem Biophys Res Commun 471 (2016), 82–88.
14. 14 Sun, C, Huang, C, Li, S, Yang, C, Xi, Y, Wang, L, et al. Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. Oncotarget 7 (2016), 8341–8359.
15. 15 Mei, Q, Xue, G, Li, X, Wu, Z, Li, X, Yan, H, et al. Methylation-induced loss of miR-484 in microsatellite-unstable colorectal cancer promotes both viability and IL-8 production via CD137L. J Pathol 236 (2015), 165–174.
16. 16 Díaz-Martín, J, Díaz-López, A, Moreno-Bueno, G, Castilla, MÁ, Rosa-Rosa, JM, Cano, A, et al. A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. J Pathol 232 (2014), 319–329.
17. 17 Hsu, CY, Hsieh, TH, Tsai, CF, Tsai, HP, Chen, HS, Chang, Y, et al. miRNA-199a-5p regulates VEGFA in endometrial mesenchymal stem cells and contributes to the pathogenesis of endometriosis. J Pathol 232 (2014), 330–343.
18. 18 Sun, CC, Li, SJ, Zhang, F, Pan, JY, Wang, L, Yang, CL, et al. Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer. Oncotarget 7 (2016), 21510–21526.
19. 19 Sun, C, Liu, Z, Li, S, Yang, C, Xue, R, Xi, Y, et al. Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation. Oncotarget 6 (2015), 25533–25574.
20. 20 Cui, R, Meng, W, Sun, HL, Kim, T, Ye, Z, Fassan, M, et al. MicroRNA-224 promotes tumor progression in nonsmall cell lung cancer. Proc Natl Acad Sci USA 112 (2015), E4288–E4297.
21. 21 Meng, W, Ye, Z, Cui, R, Perry, J, Dedousi-Huebner, V, Huebner, A, et al. MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma. Clin Cancer Res 19 (2013), 5423–5433.
22. 22 Yang, C, Sun, C, Liang, X, Xie, S, Huang, J, Li, D, Integrative analysis of microRNA and mRNA expression profiles in non-small-cell lung cancer. Cancer Gene Ther 23 (2016), 90–97.
23. 23 Yu, H, Pardoll, D, Jove, R, STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9 (2009), 798–809.
24. 24 Ernst, M, Najdovska, M, Grail, D, Lundgren-May, T, Buchert, M, Tye, H, et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 118 (2008), 1727–1738.
25. 25 Gao, SP, Mark, KG, Leslie, K, Pao, W, Motoi, N, Gerald, WL, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117 (2007), 3846–3856.
26. 26 Kortylewski, M, Xin, H, Kujawski, M, Lee, H, Liu, Y, Harris, T, et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15 (2009), 114–123.
27. 27 Crescenzo, R, Abate, F, Lasorsa, E, Tabbo', F, Gaudiano, M, Chiesa, N, et al., European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium “Genetics-Driven Targeted Management of Lymphoid Malignancies”, Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell 27 (2015), 516–532.
28. 28 Fan, QW, Cheng, CK, Gustafson, WC, Charron, E, Zipper, P, Wong, RA, et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 24 (2013), 438–449.
29. 29 Yu, H, Lee, H, Herrmann, A, Buettner, R, Jove, R, Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer 14 (2014), 736–746.
30. 30 Gough, DJ, Corlett, A, Schlessinger, K, Wegrzyn, J, Larner, AC, Levy, DE, Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 324 (2009), 1713–1716.
31. 31 Dai, B, Meng, J, Peyton, M, Girard, L, Bornmann, WG, Ji, L, et al. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res 71 (2011), 3658–3668.
32. 32 Lee, HJ, Zhuang, G, Cao, Y, Du, P, Kim, HJ, Settleman, J, Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26 (2014), 207–221.
33. 33 Ernst, M, Thiem, S, Nguyen, PM, Eissmann, M, Putoczki, TL, Epithelial gp130/Stat3 functions: an intestinal signaling node in health and disease. Semin Immunol 26 (2014), 29–37.
34. 34 Guryanova, OA, Wu, Q, Cheng, L, Lathia, JD, Huang, Z, Yang, J, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 19 (2011), 498–511.
35. 35 Kim, E, Kim, M, Woo, DH, Shin, Y, Shin, J, Chang, N, et al. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 23 (2013), 839–852.
36. 36 Lee, JH, Kim, C, Sethi, G, Ahn, KS, Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel. Oncotarget 6 (2015), 6386–6405.
37. 37 Lee, JH, Kim, C, Sethi, G, Ahn, KS, Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel. Oncotarget 6 (2015), 6386–6405.
38. 38 Sun, C, Li, S, Li, D, Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1. Oncotarget 7 (2016), 35960–35978.
39. 39 Sun, C, Huang, C, Li, S, Yang, C, Xi, Y, Wang, L, et al. Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. Oncotarget 7 (2016), 8341–8359.
40. 40 Sun, CC, Li, SJ, Zhang, F, Pan, JY, Wang, L, Yang, CL, et al. Hsa-miR-329 exerts tumor suppressor function through down-regulation of MET in non-small cell lung cancer. Oncotarget 7 (2016), 21510–21526.
41. 41 Sun, C, Li, S, Yang, C, Xi, Y, Wang, L, Zhang, F, et al. MicroRNA-187-3p mitigates non-small cell lung cancer (NSCLC) development through down-regulation of BCL6. Biochem Biophys Res Commun 471 (2016), 82–88.
42. 42 Hu, H, Li, S, Liu, J, Ni, B, MicroRNA-193b modulates proliferation, migration, and invasion of non-small cell lung cancer cells. Acta Biochim Biophys Sin (Shanghai) 44 (2012), 424–430.
43. 43 Garzon, R, Marcucci, G, Croce, CM, Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9 (2010), 775–789.
44. 44 Rajewsky, N, microRNA target predictions in animals. Nat Genet 38:Suppl (2006), S8–13.
45. 45 Grivennikov, S, Karin, M, Autocrine IL-6 signaling: a key event in tumorigenesis?. Cancer Cell 13 (2008), 7–9.
46. 46 Hong, D, Kurzrock, R, Kim, Y, Woessner, R, Younes, A, Nemunaitis, J, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med, 7, 2015, 314ra185.
47. 47 Errico, A, Lung cancer: Driver-mutation-dependent stratification: learning from STAT3. Nat Rev Clin Oncol, 12, 2015, 251.
48. 48 Fan, Z, Cui, H, Yu, H, Ji, Q, Kang, L, Han, B, et al. MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression. Oncogenesis, 5, 2016, e197.
49. 49 Hong, L, Ya-Wei, L, Hai, W, Qiang, Z, Jun-Jie, L, Huang, A, et al. MiR-519a functions as a tumor suppressor in glioma by targeting the oncogenic STAT3 pathway. J Neurooncol 128 (2016), 35–45.
50. 50 Shields, BJ, Hauser, C, Bukczynska, PE, Court, NW, Tiganis, T, DNA replication stalling attenuates tyrosine kinase signaling to suppress S phase progression. Cancer Cell 14 (2008), 166–179.
51. 51 Jeong, JB, Hong, SC, Jeong, HJ, Koo, JS, Arctigenin induces cell cycle arrest by blocking the phosphorylation of Rb via the modulation of cell cycle regulatory proteins in human gastric cancer cells. Int Immunopharmacol 11 (2011), 1573–1577.
52. 52 Sun, C, Yang, C, Xue, R, Li, S, Zhang, T, Pan, L, et al. Sulforaphane alleviates muscular dystrophy in mdx mice by activation of Nrf2. J Appl Physiol (1985) 118 (2015), 224–237.
53. 53 Sun, CC, Li, SJ, Yang, CL, Xue, RL, Xi, YY, Wang, L, et al. Sulforaphane Attenuates Muscle Inflammation in Dystrophin-deficient mdx Mice via NF-E2-related Factor 2 (Nrf2)-mediated Inhibition of NF-κB Signaling Pathway. J Biol Chem 290 (2015), 17784–17795.
54. 54 Sun, C, Li, S, Li, D, Sulforaphane mitigates muscle fibrosis in mdx mice via Nrf2-mediated inhibition of TGF-beta/Smad signaling. J Appl Physiol (1985) 120 (2016), 377–390.